We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Therapeutic Goods Act 1989
I, Peter Bird, Head, Office of Medicines Authorisation, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health for the purposes of section 42 DK (1) of the Therapeutic Goods Act, give notice that the restricted representations described in paragraph (a) below, being representations that are necessary for the appropriate use of the therapeutic goods described in paragraph (b) below, may be included either on the label of the package of the goods or in information included in the package in which those goods are contained:
- Representations to the effect that the goods described in paragraph (b) below may be used 'For the treatment of patients with known cardiovascular or cerebrovascular disease, as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischemic attack and cerebrovascular accident (stroke’ and ‘Reduces the risk of heart attack and stroke in patients with known cardiovascular or cerebrovascular disease, by helping to prevent blood clotting'
- APOHEALTH CARDIO ASPIRIN 100 mg enteric coated tablets blister pack (AUST R 229733)
- supplied as an over-the-counter medicines by Apotex Pty Ltd.
Dated this 30th day of October 2014
Dr Peter Bird
Delegate of the Secretary to the Department of Health